Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
GSK’s trio of cancer discontinuations
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
GSK prepares its kit in GIST
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
Akeso looks early in small-cell lung cancer
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
